Arcturus Therapeutics Holdings Inc. (ARCT)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Earnings Preview: Arcturus Therapeutics (ARCT) Q3 Earnings Expected to Decline
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcturus Therapeutics (ARCT) Moves 7.7% Higher: Will This Strength Last?
Arcturus Therapeutics (ARCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
4 Stocks With Recent Price Strength to Maximize Your Gains
FLUX, AUGO, ARCT and STRL are showing notable price strength amid a volatile market.
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2025 Earnings Conference Call Transcript
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q2 2025 Earnings Conference August 11, 2025 4:30 PM ET Company Participants Andrew H. Sassine - CFO & Director Joseph E.
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to a loss of $0.64 per share a year ago.
Wall Street Analysts Think Arcturus Therapeutics (ARCT) Could Surge 371.35%: Read This Before Placing a Bet
The mean of analysts' price targets for Arcturus Therapeutics (ARCT) points to a 371.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to Trade
The consensus price target hints at a 503.6% upside potential for Arcturus Therapeutics (ARCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2025 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations, Public Relations and Marketing Joe Payne - President and Chief Executive Officer Andy Sassine - Chief Financial Officer Pad Chivukula - Chief Scientific Officer and Chief Operating Officer Conference Call Participants Lili Nsongo - Leerink Partners Yasmeen Rahimi - Piper Sandler Evan Wang - Guggenheim Securities Jake Roberge - William Blair Whitney Ijem - Canaccord Genuity Samantha Schaeffer - Cantor Fitzgerald Tom Shrader - BTIG Yigal Nochomovitz - Citi Yanan Zhu - Wells Fargo Yale Jen - Laidlaw & Company Operator Good day. I would like to welcome everyone to Arcturus Therapeutics' First Quarter 2025 Earnings Call.
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $1.58. This compares to loss of $1 per share a year ago.
Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2024 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations Joe Payne - President and Chief Executive Officer, Director of the Board Andy Sassine - Chief Financial Officer Pad Chivukula - Chief Scientific Officer and Chief Operating Officer Conference Call Participants Lili Nsongo - Leerink Yasmeen Rahimi - Piper Sandler Evan Wang - Guggenheim Securities Myles Minter - William Blair Joohwan Kim - Canaccord Genuity Pete Stavropoulos - Cantor Tom Shrader - BTIG Thomas Yip - HCW Yanan Zhu - Wells Fargo Yale Jen - Laidlaw & Company Operator Good day, everyone, and welcome to today's Arcturus Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.32 per share a year ago.
